Bristol’s Transformation To Biopharma Business Progresses With Adnexus Buy
Executive Summary
Bristol-Myers Squibb is strengthening its investment in biotech treatments for cancer with its proposed acquisition of Adnexus Therapeutics
You may also be interested in...
With No Competition, BMS Looks to Complete $885 Mil. Buy of ZymoGenetics
Bristol-Myers Squibb launched its $885-million tender offer for Seattle biotech ZymoGenetics Sept. 10, with two major shareholders representing more than a third of the biotech's shares already on board. The acquisition would give Bristol full rights to a mid-stage interferon treatment for hepatitis C that it currently shares with ZymoGenetics.
With No Competition, BMS Looks to Complete $885 Mil. Buy of ZymoGenetics
Bristol-Myers Squibb launched its $885-million tender offer for Seattle biotech ZymoGenetics Sept. 10, with two major shareholders representing more than a third of the biotech's shares already on board. The acquisition would give Bristol full rights to a mid-stage interferon treatment for hepatitis C that it currently shares with ZymoGenetics.
From HCV Partner To Acquirer, BMS Makes $885 M Offer for ZymoGenetics
Ever since its pure-play biopharma strategy went into effect, Bristol-Myers Squibb has preferred buying biotechs it knows well. Hepatitis C development partner ZymoGenetics is no exception.